Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
- PMID: 19099586
- PMCID: PMC2631013
- DOI: 10.1186/1471-2407-8-381
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer
Abstract
Background: Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours. The over-expression of these proteins and their known functions in malignant neoplasms has led to the development of HDAC inhibitors (HDI) as new anti-neoplastic drugs. However, little is known about HDAC expression in renal cell cancer.
Methods: We investigated the expression of HDAC 1, 2 and 3 in 106 renal cell carcinomas and corresponding normal renal tissue by immunohistochemistry on tissue micro arrays and correlated expression data with clinico-pathological parameters including patient survival.
Results: Almost 60% of renal cell carcinomas expressed the HDAC isoforms 1 and 2. In contrast, HDAC 3 was only detected in 13% of all renal tumours, with particular low expression rates in the clear cell subtype. HDAC 3 was significantly higher expressed in pT1/2 tumours in comparison to pT3/4 tumours. Expression of class I HDAC isoforms correlated with each other and with the proliferative activity of the tumours. We found no prognostic value of the expression of any of the HDAC isoforms in this tumour entity.
Conclusion: Class I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while HDAC 3 shows low, histology dependent expression rates. These unexpected differences in the expression patterns suggests alternative regulatory mechanisms of class I HDACs in renal cell cancer and should be taken into account when trials with isoform selective HDI are being planned. Whether HDAC expression in renal cancers is predictive of responsiveness for HDI will have to be tested in further studies.
Figures




Similar articles
-
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.Br J Cancer. 2008 Feb 12;98(3):604-10. doi: 10.1038/sj.bjc.6604199. Epub 2008 Jan 22. Br J Cancer. 2008. PMID: 18212746 Free PMC article.
-
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.Lancet Oncol. 2008 Feb;9(2):139-48. doi: 10.1016/S1470-2045(08)70004-4. Lancet Oncol. 2008. PMID: 18207460
-
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.BMC Cancer. 2016 Aug 9;16:617. doi: 10.1186/s12885-016-2604-7. BMC Cancer. 2016. PMID: 27506904 Free PMC article.
-
HDAC expression and clinical prognosis in human malignancies.Cancer Lett. 2009 Aug 8;280(2):168-76. doi: 10.1016/j.canlet.2008.10.047. Epub 2008 Dec 21. Cancer Lett. 2009. PMID: 19103471 Review.
-
Explorative study on isoform-selective histone deacetylase inhibitors.Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906. doi: 10.1248/cpb.57.897. Chem Pharm Bull (Tokyo). 2009. PMID: 19721249 Review.
Cited by
-
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.Cancer Lett. 2013 Feb 1;329(1):1-8. doi: 10.1016/j.canlet.2012.09.018. Epub 2012 Sep 29. Cancer Lett. 2013. PMID: 23032720 Free PMC article. Review.
-
Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors.Int J Mol Sci. 2023 Feb 21;24(5):4263. doi: 10.3390/ijms24054263. Int J Mol Sci. 2023. PMID: 36901692 Free PMC article.
-
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC.Virchows Arch. 2011 Aug;459(2):129-39. doi: 10.1007/s00428-011-1103-0. Epub 2011 Jun 29. Virchows Arch. 2011. PMID: 21713366
-
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.Mod Pathol. 2018 Feb;31(2):264-274. doi: 10.1038/modpathol.2017.125. Epub 2017 Oct 6. Mod Pathol. 2018. PMID: 28984297 Free PMC article.
-
MicroRNAs overexpressed in Crohn's disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn's disease pathogenesis.Clin Epigenetics. 2021 Feb 18;13(1):39. doi: 10.1186/s13148-021-01022-8. Clin Epigenetics. 2021. PMID: 33602320 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous